title: Comment on spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
authors.forename: J
authors.initials: J
authors.lastname: Prezelj
authors.forename: A
authors.initials: A
authors.lastname: Kocijancic
mesh_terms: D005260:Female; D005485:Flutamide / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000627:therapeutic use; D006801:Humans; D017588:Hyperandrogenism / Q000188:drug therapy*; D010024:Osteoporosis / Q000517:prevention & control*; D013148:Spironolactone / Q000627:therapeutic use*
chemical_list: D013148:Spironolactone; D007987:Gonadotropin-Releasing Hormone; D005485:Flutamide